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Liposome co-incubation with 
cancer cells secreted exosomes 
(extracellular vesicles) with 
different proteins expressions  
and different uptake pathways
Sherif E. Emam1,3, Hidenori Ando1, Amr S. Abu Lila  1,3,5, Taro Shimizu1, Keiichiro Okuhira2, 
Yu Ishima1, Mahmoud A. Mahdy3, Fakhr-eldin S. Ghazy3, Ikuko Sagawa4 & Tatsuhiro Ishida1
We recently showed that in vitro incubation of cells with liposomes of varying compositions can increase 
exosome secretion and increase the yield of harvested exosomes (extracellular vesicles, EVs). This 
might foster their potential therapeutic implementations. In the current study, we investigated the 
surface proteins and the uptake of the harvested exosomes (EVs) to see if the incubation of cells with 
liposomes would change the biological properties of these exosomes (EVs). Interestingly, exosomes 
(EVs) induced by solid cationic liposomes lacked some major exosome marker proteins such as CD9, 
flotillin-1, annexin-A2 and EGF, and subsequently had lower levels of cellular uptake upon re-incubation 
with donor cancer cells. However, exosomes (EVs) induced under normal condition and by fluid cationic 
liposomes, displayed the entire spectrum of proteins, and exhibited higher uptake by the donor 
cancer cells. Although endocytosis was the major uptake pathway of exosomes (EVs) by tumor cells, 
endocytosis could occur via more than one mechanism. Higher exosome uptake was observed in donor 
B16BL6 cells than in allogeneic C26 cells, indicating that donor cells might interact specifically with 
their exosomes (EVs) and avidly internalize them. Taken together, these results suggest a technique 
for controlling the characteristics of secreted exosomes (EVs) by incubating donor cancer cells with 
liposomes of varying physiochemical properties.
Extracellular vesicles, EVs (exosomes) are nano-sized biological vesicles that are secreted by various cell types 
such as tumor cells, B cells and dendritic cells. They can be isolated from both extracellular biological fluid and 
conditioned culture medium1. Recent observations suggest that these natural vesicles mediate cell-cell commu-
nication in many biological processes2,3.
Since exosomes (EVs) have an innate ability to carry macromolecules such as proteins, DNA, mRNA and 
miRNAs, they have the potential to function as carriers to deliver payloads to target cells for therapeutic and diag-
nostic purposes1,4. Indeed, exosomes (EVs) have shown promising therapeutic results in the treatment of cancer, 
Parkinson’s disease and inflammatory disorders5–9. Hence, a number of clinical trials have been designed to study 
exosomes (EVs) as drug delivery tools, particularly to tumors10,11. However, therapeutic applications have been 
restricted by low exosome (EV) yields and by low uptake by the target cells; these hurdles have to be overcome 
before they can realize their potential as drug carriers12.
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We recently reported that the incubation of cancer cells with liposome formulations of different physiochem-
ical properties enhanced exosome (EV) secretion and increased exosome (EV) yield by conventional separation 
methods13. Fluid DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine)-based cationic liposomes were more 
effective than solid HSPC (hydrogenated soy phosphatidylcholine)-based liposome in increasing yield. In addi-
tion, the collected exosomes (EVs) showed different uptake propensities depending on the properties of the lipos-
ome preparations used for incubation. Uninduced exosomes (EVs) and exosomes (EVs) induced by fluid cationic 
liposomes had higher uptake than exosomes (EVs) induced by solid cationic liposomes. Further experiments are 
needed to understand the mechanisms behind these observations.
The mechanisms of interaction of exosomes (EVs) with cells and how this influences their uptake by recipient 
cells is not well understood, even the basic question of whether exosome (EV) uptake occurs through endocytosis 
or direct membrane fusion. Clarifying the mechanism of exosome (EV) uptake is the key to their development as 
drug delivery system. Many reports have demonstrated that exosome (EV) uptake by target cells is driven heter-
ogeneously via various mechanisms, depending on the nature of the exosome (EV) surface membrane proteins 
available to interact with the membrane receptors of target cells14–19. One class of exosome (EV) surface proteins 
is the tetraspanins, which are thought to be exosome (EV) markers with a role in the adhesion of exosomes (EVs) 
to recipient cells, facilitating exosome (EV) uptake20. For instance, CD9 and CD81 participate in attachment and 
uptake of exosomes (EVs) by dendritic cells15. Flotillin-1, a plasma membrane microdomain, is another exoso-
mal surface protein that controls the clathrin independent endocytosis pathway in cells16,21. In addition, EGF 
(Epidermal growth factor) is another exosomal surface protein with a predominant role in the uptake process via 
EGFR (EGF receptor)-mediated endocytosis22. Similarly, Annexin-A2 mediates endocytic entry to cells23. Other 
plausible mechanism for exosome (EV) uptake may be clathrin-dependent endocytosis, lipid raft-mediated endo-
cytosis, phagocytosis and/or macropinocytosis15,17–19.
In this study, we expanded our previous research to reveal the importance and role of exosome (EV) proteins 
in the uptake of exosomes (EVs) induced by liposomes with varying physiochemical properties. In addition, we 
have studied the uptake mechanisms of exosomes (EVs) by different cancer cell lines, induced by changing lipos-
ome properties. The results indicate that the induced exosomes (EVs) display different expression of surface pro-
teins and different endocytosis pathways, which might reflect the amount and selectivity of exosome (EV) uptake.
Results
Cellular uptake study. The cellular uptake of exosomes (EVs) collected after 48 h incubations was stud-
ied under either normal conditions (exo-N), or after stimulation with 1 mM HSPC-based liposomes (exo-S1) 
and 0.05 mM DOPE-based liposomes (exo-S2). The uptake of exo-S1 was lower than that of exo-N and exo-S2 
(Fig. 1), in agreement with our previous observations13.
Analysis of exosomal proteins. Many previous studies have reported the contribution of exosomal surface 
proteins to their cellular uptake, and have suggested their potential as drug delivery vehicles1,4,14. Accordingly, 
protein analysis of the collected exosomes (EVs) was conducted using three different techniques; shotgun anal-
ysis, SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) and Western blotting. Shotgun 
Figure 1. Uptake of exosomes (EVs) by cancer cells. The percentage of B16BL6 cells taking up exosomes (EVs) 
was evaluated by flow cytometry after incubation of PKH67-labeled exosomes (EVs) with donor cancer cells 
(B16BL6). Data represents the mean ± SD (n = 3) after subtracting the background. A one way ANOVA test 
(Tukey’s test) was applied. *p < 0.05 and **p < 0.01.
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analysis was performed to identify common exosomal markers (Table 1). Detected proteins were divided into 
four categories; tetraspanins, heat shock proteins, enzymes and others. Several common exosomal markers 
such as CD63, CD81, HSP90 and TSG101 (Tumor susceptibility gene) were shared by all collected exosomes 
(EVs). However, several other proteins such as CD9, lactate dehydrogenase A (LDHA), flotillin-1, annexin-A2, 
EGF, lysosomal membrane glycoprotein A (LAMP-2), niemann-pick disease type C1 (NPC1) and clathrin light 
chain were not detected in exo-S1. To further examine the differential expression of exosomal marker proteins, 
SDS-PAGE and Western blotting were carried out. SDS-PAGE demonstrated that all exosomes (EVs) samples 
shared most of main protein bands. But some proteins were missing in exo-S1 samples, especially in the tet-
raspanin region at 25 kDa (Supplementary Fig. 1). Exosomal proteins that might contribute to exosome (EV) 
uptake (CD9, annexin-A2, flotillin-1 and EGF) were then screened for by Western blotting analysis. As shown 
in Fig. 2, these proteins were detected at 25, 35 and 47 kDa corresponding to CD9, annexin-A2 and flotillin-1, 
respectively, in exo-N and exo-S2 (but not exo-S1) samples. In addition, in exo-N and exo-S2 samples, EGF 
showed bands at both 51 and 6 kDa, likely cleaved forms of pro-EGF (122.88 kDa). Interestingly, in exo-S1 sam-
ples, these proteins were absent or present at very low levels. It is worth noting that TSG101 (band at 47 kDa) 
was expressed equally in all exosomes (EVs) we tested confirming that equal amounts of exosomes (EVs) were 
loaded for electrophoretic separation. These results indicate that liposome stimulation caused changes in protein 
expression in derived exosomes (EVs).
Protein name
Protein hits
exo-N exo-S1 exo-S2
404 258 552
Accession 
number MW (KDa) pI
Score (peptide matches)
exo-N exo-S1 exo-S2
Tetraspanins
CD9 gi|388912 25.241 6.88 34 0 79
CD63 gi|976238 25.479 6.69 42 35 99
CD81 (Tapa-1 protein) gi|8574076 25.797 5.54 421 394 453
CD82 gi|148695678 22.373 7.98 114 68 93
CD151 (SFA-1) gi|2447007 28.257 7.44 89 62 73
Heat shock proteins
HSPA8 (HSP70.1) gi|118490060 70.088 5.53 186 107 173
HSP90 (Endoplasmin) gi|119362 92.418 4.74 117 117 115
Enzymes
Lactate dehydrogenase A (LDHA) gi|126048 36.475 7.74 79 0 26
GAPDH gi|120702 35.787 8.44 292 226 644
Alpha enolase 1 (Eno-1) gi|12832241 47.111 6.37 259 155 454
Tyrosine 3-Monooxygenase/Tryptophan 
5-Monooxygenase Activation Protein (YWHAE 
or Phopholipase A2)
gi|1304166 27.754 4.73 109 133 138
L-lactate dehydrogenase B chain isoform Ldhbx gi|938085832 37.325 5.85 119 92 82
L-lactate dehydrogenase B chain isoform 2 gi|718551069 27.989 119 85 73
Fructose-bisphosphate aldolase B gi|15723268 39.548 8.52 48 79 52
Phosphoglycerate kinase (PGK1) gi|202423 44.508 7.53 108 75 345
Chain A, Modified Glutathione S-Transferase 
(Pi) Complexed With S (P- Nitrobenzyl)
glutathione
gi|4557944 23.471 7.85 107 164 147
Others
Flotillin-1 gi|2149604 47.484 6.71 50 0 86
Annexin-A2 gi|113951 38.652 7.55 33 0 42
Epidermal growth factor (EGF) gi|49523319 122.888 6.79 39 0 24
lysosomal membrane glycoprotein A (LAMP-2) gi|293693 45.618 7.05 42 0 67
NPC1 gi|2251242 142.795 5.52 42 0 64
Clathrin (light chain) gi|34785471 23.618 4.43 116 0 116
TSG101 gi|3184260 44.096 6.28 153 121 184
Eukaryotic translation elongation factor 1 alpha 
1 (EEF1A1) gi|13278546 50.082 9.1 187 85 255
Programmed Cell Death 6 Interacting Protein 
(PDCD6IP) gi|30048422 96.251 6.15 631 219 537
Albumin (ALB) gi|3647327 68.648 5.75 550 504 878
Gamma actin gi|6425087 43.572 264 162 451
Cofilin-1 (CFL1) gi|116849 18.548 8.22 175 48 142
Ferritin heavy chain gi|309233 21.086 5.62 53 41 50
Alpha-4 integrin gi|1173604 115.013 6.29 294 381 538
Clathrin (heavy chain) gi|51491845 191.435 5.48 327 96 1768
Lactadherin (MFGE8) gi|113865979 51.208 6.11 426 80 398
Table 1. Identification of exosomal markers via shotgun analysis.
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Contribution of exosomal surface proteins to exosome (EV) uptake. The expression of EGF and 
flotillin-1 was higher in exo-N than exo-S2 samples, while annexin-A2 was higher in exo-S2. In addition, samples 
from both exosome (EV) types expressed CD9 to a similar degree. To get more insight into the role of certain 
proteins in uptake of exosomes (EVs) by cancer cells, samples of exosomes (EVs) displaying high protein expres-
sion (exo-N and exo-S2, Fig. 2) were selected for cellular uptake inhibition experiments. Briefly, labeled exosomes 
(EVs) were incubated with different antibodies (Abs) that would inhibit the interaction between surface proteins 
on exosomes (EVs) and their receptors on recipient cells, and then their uptake by donor B16BL6 (murine mel-
anoma) and allogeneic C26 (Colon 26, murine colorectal carcinoma) cells was evaluated using flow cytometry 
and confocal laser scanning microscopy. In the exo-N sample (normal exosomes, EVs), anti-CD9 Ab inhibited 
the uptake of exosomes (EVs) by B16BL6 cells by 24.1% (Fig. 3A), while anti-flotillin-1 Ab inhibited the uptake 
of exosomes (EVs) by C26 cells by 26.7% (Fig. 3B). These observations were confirmed using confocal laser 
scanning microscopy, where anti-CD9 Ab and anti-flotillin-1 Abs decreased the accumulation of exo-N (green) 
into B16BL6 and C26, respectively (Supplementary Fig. 3A). In the exo-S2 samples, anti-CD9, anti-flotillin-1 
and anti-EGF Abs inhibited the uptake of exosomes (EVs) by B16BL6 cells by 41.6%, 56.8% and 66.4%, respec-
tively (Fig. 3C). Similarly, confocal microscopy showed the decrease in the internalization of exo-S2 (green) into 
B16BL6 (Supplementary Fig. 3B). Interestingly, anti-flotillin-1 and anti-EGF Abs substantially restricted the 
uptake of exo-S2 by C26 by 61.8% and 50.1%, respectively, while anti-CD9 Ab did not inhibit the uptake by C26 
(Fig. 3D). Confocal microscopy confirmed that anti-flotillin-1 and anti-EGF Abs inhibited the uptake of exo-S2 
by C26 (Supplementary Fig. 3B). These results suggest that different surface markers may be involved in the 
uptake of exosomes (EVs) by different cells.
Exosome (EV) uptake mechanism. There have been a number of investigations into the mechanisms 
behind exosome (EV) uptake, in efforts to improve exosome-based (EV-based) drug delivery systems14. Since 
exo-N and exo-S2 showed differences in protein expression (Fig. 2) and cellular uptake (Fig. 3 and Supplementary 
Fig. 3), the mechanism mediating their uptake was further investigated.
Uptake of exo-N by B16BL6 cells or C26 cells were strongly inhibited at 4 °C, compared to normal condi-
tions (37 °C) (Fig. 4A,B). Similarly, uptake of exo-S2 by B16BL6 cells or C26 cells were strongly inhibited at 
4 °C, compared to normal conditions (37 °C) (Fig. 4A,B). These results suggest that the uptake of exo-N and 
exo-S2 by either B16BL6 cells or C26 cells was mediated by energy-dependent processes. The uptake mechanism 
Figure 2. Identification of exosomal marker proteins by Western blotting. Exosomal proteins in each sample 
(exo-N, exo-S1 and exo-S2) were electrophoretically separated and then blotted in presence of different Abs, 
including anti-CD9, anti-flotillin-1, anti-annexin-A2, anti-EGF and anti-TSG101. TSG101 was used as a 
reference (housekeeping) protein. The figure shows the cropped blots of different exosomal marker proteins 
separately and the full-length blots are presented in Supplementary Fig. 2.
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was further studied using several chemical inhibitors. The uptake of exo-N by both B16BL6 cells and C26 cells 
was inhibited by cytochalasin D, chlorpromazine (CPZ) and amiloride in a concentration-dependent manner 
(Fig. 5A,B and Supplementary Fig. 4A,B). The uptake of exo-N by both cell lines was also inhibited in the pres-
ence of filipin and sucrose (Fig. 5A,B and Supplementary Fig. 4A,B). These results indicate that exo-N were 
taken up by either B16BL6 cells or C26 cells via phagocytosis, clathrin-mediated endocytosis, lipid raft-mediated 
endocytosis and/or macropinocytosis. In the uptake of exo-S2 by either B16BL6 cells or C26 cells, similar ten-
dencies on inhibitory effect of various inhibitors were observed (Fig. 5C,D and Supplementary Fig. 4C,D). The 
uptake by B16BL6 or C26 cells was inhibited by cytochalasin D, CPZ, amiloride, filipin and sucrose (Fig. 5C,D 
and Supplementary Fig. 4C,D). These results indicate that the exo-S2 was also taken up by either B16BL6 cells or 
C26 cells via the same mechanisms as observed with exo-N. It is noteworthy that the impact of inhibitors on the 
uptake of both exo-N and exo-S2 was entirely stronger to B16BL6 cells than to C26 cells (Fig. 5A–D). This may 
suggest that B16BL6 cells highly interact with these exosomes (EVs) somehow via exosome (EV) specific surface 
protein and thus aggressively internalize them in vitro.
Discussion
In the current study, we found that exosomes (EVs) incubated with different liposome preparations expressed 
different types of proteins (Table 1). Among the three types of exosomes (EVs) we tested, exo-S1 showed the 
lowest level of protein expression and lacked several exosome (EV) marker proteins (Fig. 2). CD9, annexin-A2, 
flotillin-1 and EGF are known to contribute to exosome (EV) uptake by target cells via various mechanisms14–23. 
The lack of relevant proteins in the exo-S1 might be related to the low levels of exosome (EV) uptake by the donor 
cancer cell line (Fig. 1). Exosome (EV) preparations containing heterogeneous collections of exosomes (EVs) 
each with different protein expression may contribute to the differences in apparent uptake mechanisms observed 
in this study (Fig. 5) and various other studies14,20,24. Our current study has shown that liposome incubation with 
donor cells, depending on liposome composition, can lead to substantial changes in the protein expression in the 
exosomes (EVs), although the mechanism for this is unknown. Our finding suggests a reliable method to control 
the characteristics of derived exosomes (EVs) by changing physicochemical property of liposomes used for incu-
bation with the donor cells, allowing the fine-tuning of induced exosomes (EVs).
The current study indicated that, not only a single exosomal marker protein, but several proteins are involved 
in the interaction of exosomes (EVs) with cancer cells (Fig. 3 and Supplementary Fig. 3) and the subsequent 
Figure 3. Role of certain marker proteins in the uptake of exo-N and exo-S2 by donor cells B16BL6 and 
other allogeneic cells C26. Labeled exo-N (A and B) or exo-S2 (C and D) were incubated with different Abs 
in a ratio 1:1 for 2 h at 4 °C and then added to different cancer cell lines, namely B16BL6 (A and C) and C26 
(B and D). After 4 h incubation, cancer cells were harvested for analysis by flow cytometry. All data represent 
the mean ± SD of triplicates. An unpaired t test was applied for each value relative to untreated cancer cells, 
asterisks indicate different levels of significant difference; *p < 0.05 and **p < 0.01.
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cellular uptake of exosomes (EVs) (Figs 4, 5 and Supplementary Fig. 4). As we showed in this study, the involve-
ment of CD9, flotillins and EGF in the adhesion and targeting of exosomes (EVs) to the recipient cells has been 
highlighted in a number of previous reports7,15,25,26. Morelli and colleagues illustrated that exosomes (EVs) taken 
Figure 4. Effect of temperature on exosome (EV) uptake by donor cells (B16BL6) and allogeneic cells (C26). 
Labeled samples of exo-N and exo-S2 were incubated with different cancer cell lines at 4 °C or 37 °C. After 
2 h incubation, cancer cells were harvested for analysis by flow cytometry (A) or imaged by laser scanning 
confocal microscope after staining the DNA core with Hoechst 33342 (B). All data represent the mean ± SD 
(A) and one set (B) of triplicates. An unpaired t test was applied for each value relative to untreated cancer cells 
(***p < 0.001). Exosomes (EVs) were labeled with PHK67 (green) and the DNA core was stained with Hoechst 
33342 (blue). Scale bar indicates 20 µm.
www.nature.com/scientificreports/
7SCIenTIfIC REPORtS |  (2018) 8:14493  | DOI:10.1038/s41598-018-32861-w
up by bone marrow dendritic cells is mediated by CD915. Flotillin-1, lipid raft marker of exosomes (EVs), is 
involved in the clathrin-independent endocytosis pathway25,26. Furthermore, EGF-positive exosomes (EVs) 
are efficiently internalized by breast cancer cells in an EGFR-dependent manner7. Although the contribution of 
other proteins, not investigated in this study, to the exosome (EV) interaction with recipient cells should not be 
excluded, the exosomal interaction seems to follow a general pattern already reported.
Of note, in the interaction of exo-S2 samples with the donor cell line (B16BL6) or an unrelated cell line (C26), 
different marker proteins contributed to the interaction of the exosomes (EVs) with the recipient cell lines, i.e., 
CD-9, flotillin-1 and EGF for B16BL6 cells, and flotillin-1 and EGF for C26 cells (Fig. 3C,D and Supplementary 
Fig. 3B). This finding indicates that different cells may recognize exosomes (EVs) via different exosome (EV) 
surface markers. Hence, the specificity of exosomes (EVs) for target cells may be determined not only by charac-
teristics such as the expression pattern of surface marker proteins on the induced exosomes (EVs) but also by the 
expression pattern of the membrane receptors on the surface of the recipient cells. It has been reported that the 
exosomes (EVs) that are released by cancer cells27, can promote tumor development and are involved in mediat-
ing intercellular communication within the tumor microenvironment27,28. Despite the expected predominance 
of cancer-derived exosomes (EVs) in tumors, several studies have indicated poor in vivo tumor targetability of 
tumor-derived exosomes (EVs)6,7,29. Differential protein expression, as well as rapid clearance, may account for 
poor targetability of exosomes (EVs) in vivo6,7,29.
Confocal laser scanning microscopy allowed us to visualize the internalization of exosome (EV) samples into 
B16BL6 or C26 cells in the absence of inhibitory Abs (Supplementary Fig. 3A,B, Untreated). The result (Fig. 4) 
indicates that the internalization is an energy-dependent process, consistent with other studies15,18,30. Several 
endocytosis inhibitors significantly reduced, but didn’t completely inhibit, the uptake of exosomes (EVs) in this 
study (Fig. 5). Taken together, these results suggest that the endocytosis of exosomes (EVs) occurs through more 
than one mechanism, again consistent with previous studies18,19,30. The heterogeneity of exosome (EV) samples 
may be one reason for the differential uptake (internalization), in addition to the lack of single clear uptake mech-
anism. It is possible that a population of exosomes (EVs) can be taken up into cells via a number of different entry 
pathways, with the initial entry steps depending on the cell type and exosome (EV) composition.
Endocytosis inhibitors inhibited the uptake of exo-N and exo-S2 to a greater degree in donor B16BL6 cells 
than in C26 cells (Fig. 5). This may suggest that donor cells interact strongly with the exosome (EV) samples via 
their surface marker proteins, which in turn trigger rapid internalization. It has been reported that the uptake of 
exosomes (EVs) in vitro occurs as early as 15 min after addition19, depending on cell type. Exosomes (EVs) may 
Figure 5. Uptake mechanisms for the internalization of exo-N and exo-S2 by donor cells B16BL6 and other 
allogeneic cells C26. B16BL6 (A and C) and C26 (B and D) cancer cell lines were incubated in the presence of 
different uptake inhibitors for 30 min and then labeled exo-N (A and B) or exo-S2 (C and D) were added. After 
4 h incubation, cancer cells were harvested for analysis by flow cytometry. All data represent the mean ± SD of 
triplicates. An unpaired t test was applied for each value relative to untreated (NT) cancer cell, asterisks indicate 
different levels of significant difference; *p < 0.05, **p < 0.01 and ***p < 0.001. NT, untreated cancer cells.
www.nature.com/scientificreports/
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bind to “autocrine” receptors on donor cells that trigger rapid internalization, although further studies would be 
required to show this.
Nowadays, there is interest in applications of exosomes (EVs) as vehicles for the delivery of therapeutics to 
diseased cells4–9. However, their use is presently restricted by low exosome (EV) yields and exosome (EV) het-
erogeneity, leading to low targetability. In a previous study, we showed how the release of exosomes (EVs) from 
donor cancer cells is increased when they are incubated with liposome preparations of varying compositions13. 
In the current study, we report that incubating the donor cancer cells with liposome preparations changes the 
protein content in the induced exosomes (EVs), which raises the possibility of fine tuning exosome (EV) proper-
ties and making them more useful in drug delivery applications. Accordingly, our strategy, to employ and select 
liposome preparations as stimulators for the production of exosomes (EVs) expressing different surface protein 
markers, may be useful for engineering exosomes (EVs) for selective targeting to different diseases. Future studies 
will address these possibilities.
In conclusion, donor cells, when are exposed to liposomes of different physiochemical properties, secrete 
exosomes (EVs) with varying levels and types of protein expression, leading to their cellular uptake via several 
uptake pathways, depending on the cell type. Liposome exposure is a promising tool to fine-tune the production 
of exosomes (EVs) as drug carriers for targeted delivery of therapeutics in vitro and in vivo.
Materials and Methods
Materials. HSPC, DOPE and 1,2-dioleoyl-3-trimethylammonium-propane, chloride salt (DOTAP) were 
generously donated by NOF (Tokyo, Japan). Cholesterol (CHOL) and sucrose were purchased from Wako Pure 
Chemical (Osaka, Japan). O,O′-ditetradecanoyl-N-(alpha-trimethyl ammonio acetyl) diethanolamine chloride 
(DC-6–14) was purchased from Sogo Pharmaceutical (Tokyo, Japan). Cytochalasin D,CPZ, amiloride hydro-
chloride hydrate and filipin complex were purchased from Sigma Aldrich (MO, US). All Abs were purchased 
from Abcam (Cambridge, UK), including anti-CD9 (RabMab, ab92726), anti-annexin-A2 (ab41803), anti-flotil-
lin-1 (ab41927), anti-EGF (ab9695), anti-TSG101 (ab30871) and HRP (horseradish peroxidase) conjugated goat 
anti-rabbit IgG (immunoglobulin G) H&L (ab6721). Exosome-depleted (EV-depleted) fetal bovine serum (FBS) 
was purchased from System Biosciences (CA, US). All other reagents were of analytical grade.
Cell line and cell culture. Cancer cell lines, C26 and B16BL6, were purchased from the Cell Resource Center 
for Biomedical Research (RIKEN RBC CELL BANK, Saitama, Japan). Culture medium, consisting of RPMI1640 
(Wako Pure Chemical, Osaka, Japan) supplemented with 10% exosome-depleted (EV-depleted) FBS, 100 IU/ml 
penicillin, and 100 µg/ml streptomycin (MP Biomedicals, CA, US) was used to maintain these cells until 80–90% 
confluency. All incubation processes were carried out using 5% CO2 at 37 °C.
Preparation of liposomes. Two types of cationic liposomes, solid (HSPC-based liposomes) and fluid 
(DOPE-based liposomes), were prepared by the thin-film hydration method, as previously described13,31. The 
molar ratio of lipid composition was 2/1/0.2, HSPC/CHOL/DC-6–14 and 2/1, DOPE/DOTAP, respectively. The 
resultant large multilamellar vesicles were extruded through polycarbonate membranes with pore sizes of 400, 
200 or 100 nm using an extrusion device (TRANSFERRA Nanosciences, Inc., Burnaby, Canada). The diameters 
and zeta-potentials of prepared liposomes were determined in phosphate buffered saline (PBS) at 25 °C using 
a Zetasizer Nano ZS (Malvern Instruments Ltd., WR, U.K.). The average particle size and zeta-potential of the 
HSPC-based liposomes were 122.26 ± 2.81 nm and +10.21 ± 0.54 mV, respectively. While those of DOPE-based 
liposomes were 145.89 ± 7.59 nm and +22.18 ± 1.27 mV, respectively. The phospholipid concentration of the 
resultant liposomes was measured by a colorimetric assay32.
Exosome (EV) isolation. Exosomes (EVs) were collected from B16BL6 under normal and liposome 
incubation conditions as previously described13. Briefly, cells were maintained in exosome-depleted 
(EV-depleted) conditioned medium until 80–90% confluence. As a negative control, un-conditioned medium 
supplement with exosome-depleted (EV-depleted) FBS was tested for contaminating exosomes (EVs), mainly 
FBS-derived bovine exosomes (EVs), and proved low in contamination of exosomes (EVs) and other particles 
as probed by Nanoparticle Tracking Analysis (data not shown). For exo-N, the culture medium was replaced 
with fresh exosome-depleted (EV-depleted) conditioned medium. To obtain exo-S1 or exo-S2, the culture 
medium was replaced with fresh medium containing 1 mM HSPC-based liposomes or 0.05 mM DOPE-based 
liposomes, respectively, and further incubated. These liposome concentrations were selected to represent the 
exosome-inducing (EV-inducing) action of solid and fluid exosomes (EVs) under conditions that did not affect 
donor cell viability13. After a 48 h incubation, the culture medium was collected and centrifuged at 4 °C (200 × g 
for 10 min, 2,000 × g for 20 min and 12,500 × g for 30 min) to remove cell debris, the apoptotic bodies and microve-
sicles. Then, exosomes (EVs) were collected from the final supernatant by ultracentrifugation at 100,000 × g 
for 70 min at 4 °C. The exosome (EV) pellet was washed twice with PBS, and then dissolved in 500 μl of PBS. 
Gradient ultracentrifugation (0.3–2.5 M sucrose) was conducted to alleviate the possibility of contamination by 
liposomes. Protein concentrations of the collected exosomes (EVs) was measured by Bio-Rad DC® protein assay 
(Bio-Rad Laboratories Inc., CA, US) according to the manufacturer’s recommended protocol using a linear stand-
ard curve of bovine serum albumin (BSA) to calculate the protein concentration. The concentration and size 
distribution of the isolated exo-N, exo-S1 and exo-S2 were represented in Supplementary Fig. 5.
Shotgun analysis for exosome (EV) proteins. Shotgun analysis was conducted as described previ-
ously33. Briefly, six μg protein from exosome (EV) samples was treated with buffer A (8 M urea, 2 mM EDTA, 
250 mM Tris-HCl, pH 8.5) containing 10 mM 1,4-dithiothreitol (DTT) for 2 h at 37 °C, followed by incubation 
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with buffer A containing 25 mM iodoacetamide for 1 h at room temperature to conduct carbamidmethylation 
of the thiol group. The reaction product was mixed with 1/20 amount of trypsin solution (w/w) and incubated 
overnight at 37 °C. The resultant peptide mixture was passed through a ZipTip μ-C18 (Millipore) for desalting, 
and 0.4 μg of that was subjected to nanoLC-MS/MS analysis.
For nanoLC-MS/MS analysis, the digested peptides were separated on an Acclaim PepMap RSLC Nano 
Column (75 μm × 150 mm, 2 μm, C18, Thermo Fisher Scientific Inc., MA, US) operated at a flow rate of 
300 nL/min using UltiMate 3000 RSLCnano System (Thermo Fisher Scientific Inc., MA, US). Phase A was 0.1% 
formic acid, and phase B was 80% acetonitrile containing 0.08% formic acid. After an isocratic step at 4% B for 
10 min, B was linearly increased to 55% within 204 min followed by increase to 90% within 10 min. After 4 min 
washing, B was decreased back to 4% within 1 min. Mass spectrometry (MS) was performed using Orbitrap Elite 
(Thermo Fisher Scientific Inc., MA, US) operated in positive ion mode (Nanoflow-LC ESI). Capillary voltage was 
set at 1.7 kV. The mass data was analyzed using Mascot (Matrix Science Inc., MA, US) using the following search 
parameters; type of search (MS/MS Ion Search), enzyme (Trypsin), variable modifications (Carbamidomethyl 
(C),Oxidation (M)),mass values (Monoisotopic), protein Mass (Unrestricted), peptide mass tolerance (±10 
ppm), fragment mass tolerance (±0.6 Da), max missed cleavages (2) and instrument type (ESI-TRAP). The false 
discovery rate (FDR) is less than 1%.
SDS PAGE electrophoresis and Western blotting analysis. Exosome (EV) samples were separated 
on 5–20% gradient gels (epagele-PAGEL; ATTO, Tokyo, Japan) as previously described33. In brief, exosome (EV) 
samples were mixed with 2x sample buffer (0.1 M Tris, 4% SDS, 12% 2-mercaptoethanol, 20% glycerol, slight 
amount of bromophenol blue) in ratio 1:1 (v/v) and then heated at 95 °C for 5 min. Each lane was loaded with 
20 µl of sample containing 15 µg and 60 µg for SDS PAGE and Western blot, respectively. Electrophoresis was 
run at 25 mA per gel for 70 min. For simple SDS PAGE visualization, Precision Plus Protein All Blue Standard 
(10–250 kDa, Bio-Rad Laboratories Inc., CA, US) was used as a standard, and the gel was stained with Coomassie 
brilliant blue dye (0.05%). For Western blotting, the MagicMark™ XP Western Protein Standard (20–220 kDa, 
Thermo Fisher Scientific Inc., MA, US) was used as a standard, and the protein bands were transferred to nitro-
cellulose membranes by electrophoresis at 12 V for 30 min. The membrane was then blocked by incubating with 
5% BSA in Tris-buffered saline with 0.05% Tween 20 (TBST 0.05%) for 1 h at 37 °C and then incubated with 
a 1:1,000 dilution of different primary Abs; anti-CD9, anti-annexin-A2, anti-flotillin-1 and anti-EGF in TBST 
0.05% overnight at 4 °C. The membrane was then washed three times with TBST 0.05% and incubated with a 
1:20,000 dilution of HRP conjugated goat anti-rabbit IgG H&L secondary antibody in TBST 0.05% for 1 h at 
37 °C. The membrane was visualized by incubation with Amersham™ ECL™ Prime Western Blotting Detection 
Reagent (Sigma Aldrich, MO, US) for 5 min at room temperature then imaged using image quant LAS 4000 (GE 
Healthcare Bio-Sciences, MA, US). Exosome (EV) marker, TSG101, was used as control (housekeeping) antigens.
Evaluation of exosome (EV) uptake. The cellular uptake of different exosomes (EVs) derived from the 
donor B16BL6 melanoma cell line was evaluated in B16BL6 cells and in the allogeneic colon cancer cell line 
C26. For exosome (EV) trafficking, the exosomes (EVs) were labeled with PKH67 dye (Sigma Aldrich, MO, US) 
according to the manufacturer’s protocol with minor modifications15,34,35. Under our experimental conditions 
(sucrose gradient), excess unincorporated dye has been removed efficiently from these preparations as indicated 
by the absence of any detectable fluorescence signal after incubating the dye-control with cells and analyzed 
their cellular binding in the same manner as exosome (EV) uptake. To evaluate exosome (EV) uptake by cancer 
cells, target (recipient) B16BL6 or C26 cancer cells were cultured at 1.5 × 105 cells per well using 6 well plates. 
After 24 h incubation, labeled exosomes (EVs) were added to the cultured cells to a final concentration of 2 µg 
exosome (EV) protein/mL. After a further 2–4 h incubation, cells were harvested and exosome (EV) uptake was 
evaluated using a Gallios flow cytometer (Beckman Coulter, CA, US). The data were analyzed using Kaluza 1.2 
software (Beckman Coulter, CA, US). To further confirm exosome (EV) uptake by cancer cells, confocal micros-
copy was also employed. Briefly, target cancer cells were cultured at 3 × 104 cells in 200 µl of culture medium 
using Lab-Tek II chamber slides (Thermo Fisher Scientific Inc., MA, US) and incubated overnight. Then, labeled 
exosomes (EVs) were added and incubated with the cultured cells. After 2–4 h incubation, the culture medium 
was discarded, adhered cells were washed and then incubated with Hoechst 33342 DNA dye (1.78 µM) (Ana 
Spec Inc., CA, US) for 5 min. Adhered cells were washed twice and then left to dry for 30 min. Finally, dried cells 
were fixed with Fluoromount/Plus (Diagnostic Biosystems, CA, US) and examined via confocal laser scanning 
microscopy at 63x magnification using LSM 700 (ZEISS, Oberkochen, Germany) and LSM-ZEN2012 software 
(ZEISS, Oberkochen, Germany)15,34–36.
To study the contribution of surface proteins to exosome (EV) uptake, the inhibitory effect of different Abs 
against major exosome (EV) surface proteins (anti-CD9, anti-annexin-A2, anti-flotillin-1 and anti-EGF Abs) on 
exosome (EV) uptake was evaluated. Prior to exosome (EV) incubation with the cultured cells, labeled exosomes 
(EVs) were mixed with the selected Abs in a ratio 1:1 µg exosome (EV) protein:µg Ab and then incubated at 4 °C 
for 2 h. To study the exosome (EV) uptake mechanism, the inhibitory effect of different uptake inhibitors on 
exosome (EV) uptake was evaluated, including cytochalasin D (0.5–10 µM), CPZ (5–50 µM), amiloride hydro-
chloride (100–1000 µM), filipin complex (1–10 µg/mL) and sucrose (0.45 M). Each uptake inhibitor blocks one or 
more uptake pathway14,37; cytochalasin D blocks phagocytosis, macropinocytosis and other endocytic pathways 
via disrupting actin polymerization38–40, CPZ inhibits clathrin-dependent endocytosis by interfering with the 
assembly of clathrin in plasma membrane41, sucrose non-specifically blocks clathrin-dependent endocytosis42, 
amiloride inhibits macropinocytosis by hindering Na+/H+ exchange43 and filipin inhibits lipid raft-mediated 
endocytosis via cholesterol sequestering action44. First, the Countess II automated cell counter (Thermo Fisher 
Scientific Inc., MA, US) was adopted to evaluate cell viability after adding these inhibitors by staining cells with 
trypan blue dye. The uptake experiment was continued with inhibitor concentrations showing cell viability of 
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not less than 80% (Supplementary Fig. 6). Prior to the incubation of labelled exosomes (EVs) with the cultured 
cells for 4 h, cells were pre-incubated for 30 min at 37 °C with different concentrations of inhibitors. To evaluate 
whether exosome (EV) internalization is energy-dependent, the incubation was also done at 4 °C for 2 h.
Statistical analysis. All values were expressed as mean ± S.D. Statistical analysis was performed via 
unpaired t test or one way ANOVA test (Tukey’s test) using Graphpad Prism 6.01 software (GraphPad Software 
Inc., CA, US). The level of significance was set at *p < 0.05, **p < 0.01 and ***p < 0.001.
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